World's Best Scientists 2026 revealed!

John J. Kavanagh publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where John J. Kavanagh sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

The last bar groups every scientist with 1,796 publications or more.

John J. Kavanagh D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where John J. Kavanagh sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

The last bar groups every scientist with 217 D-Index or more.

Overview

John J. Kavanagh was affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research covered several fields within medicine, with a focus on pulmonary and respiratory medicine and oncology, alongside contributions in mechanics of materials, aerospace engineering, and materials chemistry.

Their work often addressed a variety of topics, including:

  • Metal and Thin Film Mechanics
  • High-Temperature Coating Behaviors
  • Fusion materials and technologies
  • Ovarian cancer diagnosis and treatment
  • Lung Cancer Research Studies
  • Monoclonal and Polyclonal Antibodies Research
  • Neutrophil, Myeloperoxidase and Oxidative Mechanisms

Among their frequent co-authors were Xiao Tao, Xiaoying Li, Hanshan Dong, A. Matthews, and A. Leyland.

Their recent publications reflect a diverse range of research interests spanning materials science and clinical oncology. Papers include:

  • "An investigation of precipitation strengthened Inconel 718 superalloy after triode plasma nitriding," 2022, published in Surface and Coatings Technology
  • "Phase Ib/II study of weekly topotecan and daily gefitinib in patients with platinum resistant ovarian, peritoneal, or fallopian tube cancer," 2020, published in International Journal of Gynecological Cancer
  • "SASP from lung senescent fibroblasts induces immunesenescence and fibrosis," 2020, published in The FASEB Journal
  • "Carcinoma secundário de mama por tumor metastático de ovário: relato de dois casos," 2022, published in Revista Brasileira de Cancerologia

The venues where John J. Kavanagh published included Surface and Coatings Technology, International Journal of Gynecological Cancer, The FASEB Journal, and Revista Brasileira de Cancerologia.

Best Publications

  • Anticancer therapy targeting the apoptotic pathway

    Wei Hu;John J Kavanagh

  • 13-cis-Retinoic Acid Plus Interferon α -2a: Highly Active Systemic Theraphy for Squamous Cell Carcinoma of the Cervix

    Scott M. Lippman;John J. Kavanagh;Mario Paredes-Espinoza;Fernando Delgadillo-Madrueño

  • The taxoids: paclitaxel (Taxol®) and docetaxel (Taxotere®)☆

    Richard Pazdur;Andrzej P. Kudelka;John J. Kavanagh;Philip R. Cohen

  • Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin.

    D M Gershenson;M Morris;A Cangir;J J Kavanagh

  • Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma.

    A. P. Kudelka;D. Tresukosol;C. L. Edwards;R. S. Freedman

  • Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.

    David M. Gershenson;Charlotte C. Sun;Diane Bodurka;Robert L. Coleman

  • An Assessment of the Utilization of Complementary and Alternative Medication in Women With Gynecologic or Breast Malignancies

    Marisa A. Navo;Julie Phan;Christy Vaughan;J. Lynn Palmer

  • Frequent loss of heterozygosity on chromosomes 6q, 11, and 17 in human ovarian carcinomas.

    J H Lee;J J Kavanagh;D M Wildrick;J T Wharton

  • Recombinant Human Thrombopoietin Attenuates Carboplatin-Induced Severe Thrombocytopenia and the Need for Platelet Transfusions in Patients with Gynecologic Cancer

    Saroj Vadhan-Raj;Claire F. Verschraegen;Carlos Bueso-Ramos;Carlos Bueso-Ramos;Hal E. Broxmeyer

  • Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer

    Siqing Fu;Wei Hu;Revathy Iyer;John J. Kavanagh

  • Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum

    David M. Gershenson;Charlotte C. Sun;Revathy B. Iyer;Anais L. Malpica

  • Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy.

    E. G. Hanania;R. E. Giles;J. Kavanagh;D. Ellerson

  • GnRH antagonists in the treatment of gynecological and breast cancers.

    G Emons;C Gründker;A R Günthert;S Westphalen

  • Identification of an IL-10-Producing HLA-DR-Negative Monocyte Subset in the Malignant Ascites of Patients with Ovarian Carcinoma That Inhibits Cytokine Protein Expression and Proliferation of Autologous T Cells

    Amy E. Loercher;Micheal A. Nash;John J. Kavanagh;Chris D. Platsoucas

  • A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix.

    Andrzej P. Kudelka;Tally Levy;Claire F. Verschraegen;Creighton L. Edwards

  • Efficacy and safety of liposomal anthracyclines in Phase I/II clinical trials

    David S. Alberts;Franco M. Muggia;James Carmichael;Eric P. Winer

  • Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix

    C. F. Verschraegen;T. Levy;A. P. Kudelka;E. Llerena

  • Vulvar melanoma at the M. D. Anderson Cancer Center: 25 years later

    C. F. Verschraegen;M. Benjapibal;W. Supakarapongkul;L. B. Levy

  • Ovarian cancer, the coagulation pathway, and inflammation

    Xipeng Wang;Ena Wang;John J Kavanagh;Ralph S Freedman

  • Staging Classifications and Clinical Practice: Guidelines for Gynaecologic Cancers

    JL Benedet;Sergio Pecorelli;Hextan Ys Ngan;Lynne Denny

Frequent Co-Authors

David M. Gershenson
David M. Gershenson The University of Texas MD Anderson Cancer Center
Elvio G. Silva
Elvio G. Silva The University of Texas MD Anderson Cancer Center
Robert C. Bast
Robert C. Bast The University of Texas MD Anderson Cancer Center
Scott M. Lippman
Scott M. Lippman University of California, San Diego
Michael T. Deavers
Michael T. Deavers Houston Methodist
Robert L. Coleman
Robert L. Coleman The University of Texas MD Anderson Cancer Center
Albert B. Deisseroth
Albert B. Deisseroth US Food and Drug Administration
Anais Malpica
Anais Malpica The University of Texas MD Anderson Cancer Center
Anil K. Sood
Anil K. Sood The University of Texas MD Anderson Cancer Center
Pedro Tomas Ramirez
Pedro Tomas Ramirez The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in healthcare but not ready for the commitment of a full medical degree, many rewarding alternatives exist. Numerous accredited online programs equip students for vital healthcare roles—often with flexible schedules and accessible admissions.

For example, those seeking administrative roles can find excellent options with a health care administration degree. These programs prepare graduates for leadership positions in hospitals and clinics, often in under four years.

If you prefer direct patient care, becoming an LPN or RN is a popular pathway. Some schools offer lpn school without teas test requirements, making entry less stressful for prospective students. For current RNs seeking career advancement, there are many convenient rn to np programs online that bridge the gap to Nurse Practitioner roles.

If you’re interested in the technical side of healthcare, financial aid for medical billing and coding programs can help you break into this fast-growing field, often with lower tuition costs and flexible payment options.

Best Scientists Citing John J. Kavanagh

Recently Published Articles